AMANTA
Amanta Healthcare financials
- Market cap
- ₹645 Cr
- Sector
- Healthcare
- Calls analysed
- 3
Amanta Healthcare Limited Q1 FY27
What went well
- Revenue grew by 5% year-on-year to INR69 crores, indicating resilient financial performance.
- Maintained a healthy EBITDA margin of approximately 22% (INR15 crores EBITDA) despite cost pressures.
- SteriPort Line 3 received FDA approval, with commercial production anticipated by the last week of August 2026, expected to contribute INR70 crores in top line for the remaining 7 months of FY27.
What to watch
- SteriPort expansion was delayed from Q1 to Q2 FY27 due to operational delays, primarily civil construction activity.
- Experienced cost pressures from polymer price volatility (a short-lived 70-80% spike) and overheads absorbed due to expansion ahead of commercialization.
What Amanta Healthcare Limited does
Amanta Healthcare manufactures sterile liquid pharmaceuticals across six therapeutic segments: IV fluids (Large Volume Parenterals), Small Volume Parenterals, diluents & injectables, ophthalmic solutions, respiratory solutions and irrigation solutions. It uses Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch-Blow Moulding (ISBM) technologies, including its proprietary SteriPort two-port IV bottle platform, to produce sterile liquids with minimal human contact. The company sells domestically under its own brand names through a distributor network and exports formulations to emerging and semi-regulated international markets under product registrations in many jurisdictions.
Segments
- Fluid Therapy (IV Fluids)
- Formulations (Injectables/Ophthalmic/Respiratory)
- Diluents & Injectables
- Ophthalmic Solutions
- Respiratory Solutions
- Irrigation Solutions
- SteriPort
- Manufacturing facility
- 1 WHO-GMP facility spanning 66,852 sq. meters (Hariyala, Kheda, Gujarat)
- Production lines
- 7 (LVP 4 lines, SVP 3 lines)
- Installed capacity - LVP (incl. SteriPort)
- 12.28 crore bottles/yr
- Installed capacity - SVP
- 20.91 crore units/yr
- Product portfolio
- 47 products
- Distributors & stockists
- 320+
Guidance record · Q1 FY27
what the last two calls moved 17 tracked 1 delivered 1 missed 15 open- Solar Plant Cost Savings delivered said Q3 FY26 Promised: ₹9 crores annual EBITDA level savings from Q1 FY27 Q1 FY27: The 10.8 MW captive solar power project was commissioned in June 2026. Management confirmed it is projected to save ₹75 lakhs per month, achieving the annualized target.
- Debt Refinancing went quiet said Q4 FY26 Promised: Replace around ₹30 crores to ₹40 crores of debt with lower interest rate in next six months Q1 FY27: No specific update was provided on the status of this refinancing activity targeted for H1 FY27 (ending Sep 2026).
- LVP SteriPort Capacity Commercialization delayed said Q3 FY26 Promised: 12 crore bottles per annum by April 2026 Q1 FY27: Commissioning delayed from Q1 to Q2 due to civil construction issues. Commercial production now anticipated by the last week of August 2026.
All 17 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 5.3%, net profit down 5.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 67 | 68 | 72 | 65 | 71 +6% | 74 +10% | 77 +7% | 69 +5% |
| EBITDA | 14 | 15 | 19 | 15 | 15 +6% | 15 +2% | 15 −21% | 15 −2% |
| Net profit | 2 | 4 | 6 | 4 | 1 −46% | 5 +8% | 6 −7% | 3 −6% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +33.0% 1Y
1Y: ₹148.72 on 10 Sept 2025 → ₹197.75. High ₹205.89 (9 Sept 2026), low ₹95.03 (17 Mar 2026).
How the price took the results
close before → close after
- Q1 FY27
- −2.0%
- 6 Aug
- Q4 FY26
- −0.1%
- 21 May
- Q3 FY26
- +2.1%
- 11 Feb
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 4.7% a year over 1 year, FY25 to FY26. Operating margin narrowed to 20.8%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹275 Cr | ₹288 Cr |
| Operating profit | ₹61 Cr | ₹60 Cr |
| Operating margin | 22.3% | 20.8% |
| Interest | ₹28 Cr | ₹21 Cr |
| Depreciation | ₹18 Cr | ₹19 Cr |
| Net profit | ₹12 Cr | ₹15 Cr |
| Net margin | 4.4% | 5.2% |
| Cash from operations | ₹47 Cr | ₹48 Cr |
| Free cash flow | ₹26 Cr | ₹-32 Cr |
| ROCE | 15.0% | 12.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹27 Cr | ₹27 Cr | ₹27 Cr | ₹27 Cr | ₹39 Cr | ₹39 Cr |
| Reserves | ₹-20 Cr | ₹36 Cr | ₹36 Cr | ₹39 Cr | ₹172 Cr | ₹181 Cr |
| Borrowings | ₹235 Cr | ₹226 Cr | ₹216 Cr | ₹211 Cr | ₹186 Cr | ₹244 Cr |
| Other liabilities | ₹150 Cr | ₹104 Cr | ₹96 Cr | ₹75 Cr | ₹92 Cr | ₹93 Cr |
| Total liabilities | ₹392 Cr | ₹392 Cr | ₹374 Cr | ₹352 Cr | ₹488 Cr | ₹558 Cr |
| Fixed assets | ₹242 Cr | ₹240 Cr | ₹232 Cr | ₹228 Cr | ₹210 Cr | ₹207 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹9 Cr | ₹0 Cr | ₹11 Cr | ₹82 Cr |
| Investments | ₹2 Cr | ₹3 Cr | ₹0 Cr | ₹4 Cr | ₹8 Cr | ₹7 Cr |
| Other assets | ₹149 Cr | ₹149 Cr | ₹133 Cr | ₹120 Cr | ₹259 Cr | ₹262 Cr |
| Total assets | ₹392 Cr | ₹392 Cr | ₹374 Cr | ₹352 Cr | ₹488 Cr | ₹558 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
All earnings calls (3)
Read the Q1 FY27 call →Learn to analyse Amanta Healthcare Limited
Guides on how to read this kind of business and the numbers that matter.